Cozart gets RapiScan vote of confidence in UK, expands overseas
This article was originally published in Clinica
The pace of business for UK immunodiagnostics company Cozart Bioscience is hotting up. The Abingdon-based company is planning a worldwide launch (except US) of its sensitive on-site RapiScan test for detecting buprenorphine use and nor- buprenorphine in urine. The analgesic is used as an alternative to methadone in moving patients off heroine and opiates, and the kit will be a useful tool helping staff in drug dependency clinics to check rapidly - within ten minutes - if patients are complying with their treatment regimes. The launch will take place next month.